OCUGEN A Speculation And Risk Play For Huge Upside
<p>Stock is trading near all-time lows as of 7/6/2020.</p>
<p>Expansive gene therapy pipeline with FDA orphan designation of OCU400.</p>
<p>Insider purchases in recent months and no reported sales.</p>
<p>Discontinued phase trial of drug candidate OCU300.</p>
<p>On June 1, the company discontinued their Phase 3 trial of “OCU300” for ocular Graft vs. Host Disease (oGVHD).” This follows the results of a pre-planned interim sample size, which indicated that the trial is unlikely to meet co-primary endpoints upon completion.” Despite this, Ocugen’s stock closed up 11% on June 5, indicating the firm’s soaring optimism and anticipated recovery.</p>
<p><a href="https://medium.datadriveninvestor.com/ocugen-a-speculation-and-risk-play-for-huge-upside-9c6155133ad5"><strong>Visit Now</strong></a></p>